摘要
目的:探讨吉非替尼靶向治疗联合化疗治疗非小细胞肺癌的临床效果。方法:选择2017年1月—2018年1月80例非小细胞肺癌(NSCLC)化疗患者,随机分为化疗组和联合组,每组40例。化疗组采用GP(吉西他滨和顺铂)化疗方案,联合组在化疗组基础上联合吉非替尼治疗,250mg/次,1次/d,连续治疗21d,休息7d,为1个疗程,共治疗4个疗程。观察两组近期疗效,比较两组治疗前、后免疫功能和营养状况。结果:联合组治疗有效率为77. 50%,高于化疗组的55. 00%(P <0. 05)。治疗前,两组CD4+、CD8+、CD4+/CD8+差异无统计学意义(P> 0. 05),治疗后,联合组CD4+、CD4+/CD8+高于化疗组(P <0. 05),CD8+低于化疗组(P <0. 05)。治疗前,两组体重指数(BMI)、血红蛋白(Hb)、白蛋白(ALB)比较差异无统计学意义(P> 0. 05),治疗后,联合组BMI、Hb、ALB均高于化疗组(P <0. 05)。结论:吉非替尼靶向治疗联合化疗可提高NSCLC患者的近期疗效和免疫功能,改善营养状况。
Objective：To explore the clinical effect of gefitinib targeted therapy combined with chemotherapy in the treatment of non-small cell lung cancer. Methods：80 patients with non-small cell lung cancer （NSCLC） undergoing chemotherapy, selected from January 2017 to January 2018, were randomly divided into chemotherapy group and combined group with 40 cases in each group. Chemotherapy group was treated with GP （gemcitabine and cisplatin）, combined group was treated with gefitinib（250mg/times, 1 times/d, ） on the basis of chemotherapy group, and one course of treatment was continuous 21 days with rest 7 days, a total course was 4 courses. The short-term efficacy was observed in the two groups, and the immune function and nutritional status were compared before and after treatment in the two groups. Results：The effective rate in combined group was 77.50%, which was higher than that（55.00% ） in chemotherapy group （P 〈 0.05）. Before treatment, there were no significant difference in CD4 ＋ , CD8 ＋ and CD4 ＋/CD8 ＋ in the two groups （P 〉 0.05）. After treatment, CD4 ＋ and CD4 ＋/CD8 ＋ in combined group were higher than those in chemotherapy group （ P 〈 0.05 ） , and CD8 ＋ was lower than that in chemotherapy group （P 〈 0.05 ）. Before treatment, there were no significant difference in body mass index（ B MI）, hemoglobin （Hb） and albumin （ALB） in the two groups （P 〉 0.05 ）. After treatment, BMI, Hb and ALB in combined group were all higher than those in chemotherapy group （ P 〈 0.05 ）. Conclusion ： Gefitinib targeted therapy combined with chemotherapy could improve the short-term curative effect, improve immune function and nutritional status in patients with NSCLC.
作者
任书娟
陆超
邵夏霞
REN Shujuan;LU Chao;SHAO Xiaxia(Medical Oncology of the Affiliated Jiangyin Hospital of Southeast University Medical College,Jiangyin City,Jiangsu Province 214400)
出处
《医学理论与实践》
2018年第22期3322-3324,共3页
The Journal of Medical Theory and Practice
关键词
非小细胞肺癌
吉非替尼靶向治疗
化疗
Non-small cell lung cancer
Gefitinib targeted therapy
Chemotherapy
